2024-03-29T02:07:51Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:02001673
2022-04-27T09:50:44Z
2780:2179
2780:5275
2780:5276
2780:5694
2780:5695
2780:5696
2780:8116
3:62:5592:1634626328232
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer
中尾, 砂理
ナカオ, サリ
NAKAO, Sari
水口, 剛雄
ミナグチ, タケオ
MINAGUCHI, Takeo
Itagaki, Hiroya
Hosokawa, Yoshihiko
志鎌, あゆみ
シカマ, アユミ
SHIKAMA, Ayumi
田坂, 暢崇
タサカ, ノブタカ
TASAKA, Nobutaka
秋山, 梓
アキヤマ, アズサ
AKIYAMA, Azusa
越智, 寛幸
オチ, ヒロユキ
OCHI, Hiroyuki
Matsumoto, Koji
佐藤, 豊実
サトウ, トヨミ
SATOH, Toyomi
open access
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Methods
We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011.
Results
Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition (P = 0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n = 126), thrombocytosis was associated with a shorter treatment-free interval (TFI) (P = 0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA (P = 0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis (P < 0.0001 and < 0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS (P = 0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA.
Conclusions
The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease.
BMC
2020-05
eng
journal article
http://hdl.handle.net/2241/0002001673
https://tsukuba.repo.nii.ac.jp/records/2001673
32375852
https://doi.org/10.1186/s13048-020-00651-6
1757-2215
Journal of Ovarian Research
13
1
55
https://tsukuba.repo.nii.ac.jp/record/2001673/files/JOR_13-55.pdf
application/pdf
882 KB
2021-10-25